Expansion of Mesenchymal Stem/Stromal Cells under Xenogenic-Free Culture Conditions
Expansion of Mesenchymal Stem/Stromal Cells under Xenogenic-Free Culture Conditions
复制标题
DOI：
10.1007/10_2012_134
复制
发表时间：
2013-01-01
期刊：
影响因子：
--
通讯作者：
Bieback, Karen
中科院分区：
文献类型：
--
作者：
Kinzebach, Sven;Bieback, Karen
间充质干/基质细胞（MSC）越来越多地应用于基于细胞的再生医学。为了产生临床相关的细胞剂量，需要MSC的离体扩增符合良好生产规范（GMP）指南。缺乏标准化和协调似乎阻碍了翻译阶段的快速进展。大多数方案仍然使用胎牛血清（FBS）来扩增MSC。然而，高批间变异性、污染风险和免疫要求无异种培养条件。化学成分确定的培养基是标准化方面的最终成就。然而，这些培养基需要保持MSC的所有关键细胞和治疗相关特征。由于FBS的成分众多，因此具有几个基本因子的最佳组成的这种化学成分确定的培养基的开发才刚刚开始。与此同时，各种人血衍生成分正在研究中，包括人血浆、人血清、人脐带血血清和人血小板衍生物如血小板裂解物。
Mesenchymal Stem/Stromal cells (MSCs) are increasingly applied in cell-based regenerative medicine. To yield clinically relevant cell doses, ex vivo expansion of MSCs is required to be compliant with good manufacturing practice (GMP) guidelines. A lack of standardization and harmonization seems to hamper rapid progress in the translational phase. Most protocols still use fetal bovine serum (FBS) to expand MSCs. However, the high lot-to-lot variability, risk of contamination and immunization call for xenogenic-free culture conditions. Chemically defined media are the ultimate achievement in terms of standardization. These media, however, need to maintain all key cellular and therapy-relevant features of MSCs. Because of the numerous constituents of FBS, the development of such chemically defined media with an optimal composition of the few essential factors is only beginning. Meanwhile, various human blood-derived components are under investigation, including human plasma, human serum, human umbilical cord blood serum and human platelet derivatives such as platelet lysate.